Physician profile
Juli Garner Horton
NPI 1679568364
$14,273.04
in general payments reported to CMS, 2019-2025
41 companies · $2,743 in 2025
The $2,743 reported for 2025 was more than what 88% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $1,032 · 2021: $1,353 · 2022: $2,285 · 2023: $2,290 · 2024: $2,617 · 2025: $2,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,553 · Education: $97.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,552.70 |
| Education | $97.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,903.44 | 2019-2025 | Veklury, Biktarvy |
| Janssen Biotech, INC. | $1,593.53 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Viiv Healthcare Company | $1,455.53 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Abbvie INC. | $1,422.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,011.89 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Theratechnologies INC. | $646.23 | 2019-2025 | Egrifta, Trogarzo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $618.81 | 2019-2025 | Xifaxan |
| Insmed, INC. | $598.73 | 2019-2025 | Arikayce, Brinsupri |
| La Jolla Pharmaceutical Company | $466.54 | 2020-2025 | Xacduro, Zevtera, Xerava |
| Cumberland Pharmaceuticals, INC. | $440.34 | 2023-2025 | Vibativ |
| Takeda Pharmaceuticals U.S.A., INC. | $415.07 | 2020-2025 | Entyvio, Eohilia, Livtencity |
| Shionogi INC | $388.35 | 2021-2025 | Fetroja |
| Astellas Pharma US INC | $341.52 | 2023-2025 | Cresemba |
| Janssen Products, Lp | $334.46 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $216.91 | 2022-2024 | Rebyota |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juli Horton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.